Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?

Trends in Pharmacological Sciences

Volumn 37, Issue 6, 2016, Pages 419-434

  Borea, Pier Andrea ^a   Gessi, Stefania ^a   Merighi, Stefania ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

adenosine; adenosine receptors; cancer; inflammation; ischaemia; pain

Indexed keywords

ADENOSINE; CYCLIC AMP; PICLIDENOSON; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE;

AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; DISEASES; ENTERITIS; EPILEPSY; HUMAN; HYDROLYSIS; INFLAMMATORY PAIN; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; NUCLEIC ACID METABOLISM; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS VULGARIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; BRAIN; METABOLISM;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN; HUMANS; RECEPTORS, PURINERGIC P1;

EID: 84959422285     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.02.006     Document Type: Review

References (142)

1. 3 adenosine receptor: history and perspectives Pharmacol. Rev. 67 2015 74 102
2. B.B. Fredholm Adenosine - a physiological or pathological agent? J. Mol. Med. 92 2014 201 206
3. B.B. Fredholm, and et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update Pharmacol. Rev. 63 2011 1 34
4. J. Linden Adenosine in tissue protection and tissue regeneration Mol. Pharmacol. 67 2005 1385 1387
5. D. Boison Adenosinergic signaling in epilepsy Neuropharmacology 2015 10.1016/j.neuropharm.2015.08.046 Published online September 1, 2015
6. S.A. Masino Adenosine receptors and epilepsy: current evidence and future potential Int. Rev. Neurobiol. 119 2014 233 255
7. 1-receptor activation Epilepsia 53 2012 168 176
8. 2A receptors and 5′-nucleotidase activity in rat cerebral cortex J. Neurochem. 134 2015 395 404
9. 1 receptors J. Clin. Invest. 121 2011 2679 2683
10. S.A. Masino, and et al. Purines and neuronal excitability: links to the ketogenic diet Epilepsy Res. 100 2012 229 238
11. T.A. Lusardi, and et al. Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats Neuropharmacology 99 2015 500 509
12. R.L. Williams-Karnesky, and et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis J. Clin. Invest. 123 2013 3552 3563
13. K. Kobow, and I. Blümcke The emerging role of DNA methylation in epileptogenesis Epilepsia 53 2012 11 20
14. D. Boison Adenosine kinase: exploitation for therapeutic gain Pharmacol Rev. 65 2013 906 943
15. P. Theofilas, and et al. Adenosine kinase as a target for therapeutic antisense strategies in epilepsy Epilepsia 52 2011 589 601
16. D. Boison, and E. Aronica Comorbidities in neurology: is adenosine the common link? Neuropharmacology 97 2015 18 34
17. D. Boison, and H.Y. Shen Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death Open Drug Discov J. 2 2010 108 118
18. F. Ciruela, and et al. G protein-coupled receptor oligomerization and brain integration: focus on adenosinergic transmission Brain Res. 1476 2012 86 95
19. C. Gomes, and et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia J. Neuroinflammation. 10 2013 16
20. F. Pedata, and et al. Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia Mediators Inflamm. 2014 2014 805198
21. 1 receptor activation modulates N-methyl-d-Aspartate (NMDA) preconditioning phenotype in the brain Behav. Brain Res. 282 2015 103 110
22. E.K. Iliodromitis, and et al. Ischemic and postischemic conditioning of the myocardium in clinical practice: challenges, expectations and obstacles Cardiology 129 2014 117 125
23. T. Eckle, and et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia Nat. Med. 18 2012 774 782
24. 2B adenosine receptors Trends Mol. Med. 19 2013 345 354
25. S.W. Seo, and et al. Differential tissue-specific function of Adora2b in cardioprotection J. Immunol. 195 2015 1732 1743
26. K. Koda, and et al. Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells Circulation 122 2010 771 781
27. 3 adenosine receptor: an enigmatic player in cell biology Pharmacol. Ther. 117 2008 123 140
28. 3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts BMC Pharmacol. 11 2011 11
29. V.J. McIntosh, and R.D. Lasley Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J. Cardiovasc. Pharmacol. Ther. 17 2012 21 33
30. 3 adenosine receptor J. Pharmacol. Exp. Ther. 340 2012 210 217
31. 3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches Med. Res. Rev. 33 2013 235 335
32. 3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells J. Mol. Cell. Cardiol. 49 2010 280 286
33. 3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction Cardiovasc. Drugs Ther. 28 2014 19 32
34. 2A receptors Basic Res. Cardiol. 110 2015 16
35. 2A receptor agonist Am. J. Physiol. Heart Circ. Physiol. 297 2009 H637 H642
36. H.A. Johnston-Cox, and K. Ravid Adenosine and blood platelets Purinergic Signal. 7 2011 357 365
37. 2A receptors in ischemia reperfusion injury and islet transplantation Curr. Diabetes Rev. 8 2012 419 833
38. C.B. Fordyce, and et al. Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury Trends Pharmacol. Sci. 36 2015 605 616
39. G. Niccoli, and et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction) JACC Cardiovasc. Interv. 6 2013 580 589
40. G. Niccoli, and et al. REOPEN-AMI Investigators. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial J. Am. Coll. Cardiol. 63 2014 1454 1455
41. S.A. Nazir, and et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial Trials 15 2014 371
42. 3 adenosine receptors attenuates lung ischemia-reperfusion injury J. Thorac. Cardiovasc. Surg. 140 2010 440 446
43. 2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model J. Thorac. Cardiovasc. Surg. 142 2011 887 894
44. 1 receptor activation attenuates lung ischemia-reperfusion injury J. Thorac. Cardiovasc. Surg. 145 2013 1654 1659
45. 3 receptor activation attenuates lung ischemia-reperfusion injury Ann. Thorac. Surg. 95 2013 1762 1767
46. 2B adenosine receptors in pulmonary protection during acute lung injury J. Immunol. 195 2015 1815 1824
47. A. Grenz, and et al. Extracellular adenosine: a safety signal that dampens hypoxia-induced inflammation during ischemia Antioxid Redox Signal. 15 2011 2221 2234
48. L. Li, and et al. Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury J. Clin. Invest. 122 2012 3931 3942
49. 2B adenosine receptors dampens ischemia and reperfusion injury of the liver Proc. Natl. Acad. Sci. U.S.A. 110 2013 12012 12017
50. 2AR stimulation J. Hepatol. 62 2015 573 580
51. A. Grenz, and et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice J. Clin. Invest. 122 2012 693 710
52. 2B receptor inhibition on VEGF and nitric oxide axis-mediated renal function in diabetic nephropathy Ren. Fail. 36 2014 916 924
53. M.J. Zylka Pain-relieving prospects for adenosine receptors and ectonucleotidases Trends Mol. Med. 17 2011 188 196
54. R.L. Rauck, and et al. Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome Pain 156 2015 88 95
55. 1 receptors Eur. J. Pharmacol. 674 2012 248 254
56. 1 receptors contribute to antinociception by tramadol in the formalin test in mice Eur. J. Pharmacol. 714 2013 373 378
57. J. Sawynok Adenosine receptor targets for pain Neuroscience 2015 10.1016/j.neuroscience.2015.10.031 Published online October 21, 2015
58. R. Romagnoli, and et al. Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development Curr. Med. Chem. 17 2010 3488 3502
59. N. Sowa, and et al. Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-biphosphate J. Neurosci. 30 2010 10282 10293
60. F. Luongo, and et al. The A1 adenosine receptor as a new player in microglia physiology Glia 62 2014 122 132
61. F. Vincenzi, and et al. TRR469, a potent A1 adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice Neuropharmacology 81 2014 6 14
62. W.L. Imlach, and et al. A positive allosteric modulator of the adenosine A1 receptor selectively inhibits primary afferent synaptic transmission in a neuropathic pain model Mol. Pharmacol. 88 2015 460 468
63. K. Otsuguro, and et al. An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat Neuropharmacology 97 2015 160 170
64. F.P. Nascimento, and et al. Adenosine A1 receptor-dependent antinociception induced by inosine in mice: pharmacological, genetic and biochemical aspects Mol. Neurobiol. 51 2015 1368 1378
65. Z. Chen, and et al. Prolonged adenosine A1 receptor activation in hypoxia and pial vessel disruption focal cortical ischemia facilitates clathrin-mediated AMPA receptor endocytosis and long-lasting synaptic inhibition in rat hippocampal CA3-CA1 synapses: differential regulation of GluA2 and GluA1 subunits by p38 MAPK and JNK J. Neurosci. 34 2014 9621 9643
66. N. Goldman, and et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture Nat. Neurosci. 13 2010 883 888
67. W. Ren, and et al. Electroacupuncture improves neuropathic pain: adenosine, adenosine 5′-triphosphate disodium and their receptors perhaps change simultaneously Neural Regen. Res. 7 2012 2618 2623
68. J.Y. Wang, and et al. Adenosine as a probing tool for the mechanistic study of acupuncture treatment Clin. Exp. Pharmacol. Physiol. 41 2014 933 939
69. L.C. Loram, and et al. Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling Brain Behav. Immun. 33 2013 112 122
70. K. Janes, and et al. Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics Br. J. Pharmacol. 2016 10.1111/bph.13446 Published online January 25, 2016
71. Z. Chen, and et al. Controlling murine and rat chronic pain through A3 adenosine receptor activation FASEB J. 26 2012 1855 1865
72. 3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways Pain 155 2014 2560 2567
73. S. Gessi, and et al. A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes Pharmacol. Res. 76 2013 157 170
74. 3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy Brain Behav. Immun. 44 2015 91 99
75. A. Ford, and et al. Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain J. Neurosci. 35 2015 6057 6067
76. 3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model Eur. J. Cancer 49 2013 482 491
77. P. Fishman, and et al. Pharmacological and therapeutic effects of A3 adenosine receptor agonists Drug Discov. Today 17 2012 359 366
78. D.K. Tosh, and et al. Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain Purinerg. Signal. 11 2015 371 387
79. J.W. Little, and et al. Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states Brain 138 2015 28 35
80. K.E. Barletta, and et al. Regulation of neutrophil function by adenosine Arterioscl. Throm. Vas. 32 2012 856 864
81. G. Hasko, P. Pacher, and et al. Regulation of macrophage function by adenosine Arterioscl. Throm. Vas. 32 2012 865 869
82. J. Linden, and C. Cekic Regulation of lymphocyte function by adenosine Arterioscl. Throm. Vas. 32 2012 2097 2103
83. F. Vincenzi, and et al. Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated Eur. J. Immunol. 43 2013 2206 2216
84. L. Antonioli, and et al. Adenosine and inflammation: what's new on the horizon? Drug Discov. Today 19 2014 1051 1068
85. M. Perretti, and et al. Resolution pharmacology: opportunities for therapeutic innovation in inflammation Trends Pharmacol. Sci. 36 2015 737 755
86. A. Ohta, and et al. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage Nature 414 2001 916 920
87. C.M. Aherne, and et al. The resurgence of A2B adenosine receptor signaling Biochim. Biophys. Acta. 1808 2011 1329 1339
88. M. Koeppen, and et al. The hypoxia-inflammation link and potential drug targets Curr. Opin. Anaesthesiol. 24 2011 363 369
89. J.M. Poth, and et al. Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease J. Mol. Med. 91 2013 183 193
90. G. Haskó, and B. Cronstein Regulation of inflammation by adenosine Front. Immunol. 4 2013 85
91. E.S. Chan, and B. Cronstein Methotrexate-how does it really work? Nat. Rev. Rheumatol. 6 2010 175 178
92. E.S. Chan, and B.N. Cronstein Mechanisms of action of methotrexate Bull. Hosp. Jt. Dis. 71 Suppl. 1 2013 S5 S8
93. R.S. Peres, and et al. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis Proc. Natl. Acad. Sci. U.S.A. 112 2015 2509 2514
94. E. Mazzon, and et al. CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis J. Rheumatol. 38 2011 2119 2129
95. U. Flogel, and et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis Sci. Transl. Med. 4 2012 146ra108
96. K. Varani, and et al. A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release Arthritis Res. Ther. 13 2011 R197
97. N.D. Khoa, and et al. Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells J. Immunol. 167 2001 4026 4032
98. M. Perez-Aso, and et al. Adenosine A2A receptor and TNF-α regulate the circadian machinery of the human monocytic THP-1 cells Inflammation 36 2013 152 162
99. C.J. Ferrante, and et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling Inflammation 36 2013 921 931
100. M. David, and et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial J. Eur. Acad. Dermatol. 26 2012 361 367
101. A. Mediero, and et al. Adenosine A2A receptor activation prevents wear particle-induced osteolysis Sci. Transl. Med. 4 2012 135ra65
102. A. Mediero, B.N. Cronstein, and et al. Adenosine and bone metabolism Trends Endocrin. Met. 24 2013 290 300
103. A. Mediero, and et al. Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocation Br. J. Pharmacol. 169 2013 1372 1388
104. A. Mediero, and et al. Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2 FASEB J. 29 2015 1577 1590
105. B. Gharibi, and et al. Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes J. Bone Miner. Res. 26 2011 2112 2124
106. S.H. Carroll, and et al. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo J. Biol. Chem. 287 2012 15718 15727
107. M. Takedachi, and et al. CD73-generated adenosine promotes osteoblast differentiation J. Cell. Physiol. 227 2012 2622 2631
108. W. He, and et al. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma FASEB J. 27 2013 3446 3454
109. 3 adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts PLoS ONE 8 2013 e65561
110. D. Ferrari, and et al. Purinergic signaling in scarring FASEB J. 30 2016 3 12
111. J. Arasa, and et al. Topical application of the adenosine A2A receptor agonist CGS-21680 prevents phorbol-induced epidermal hyperplasia and inflammation in mice Exp. Dermatol. 23 2015 555 560
112. S. Gessi, and et al. Targeting adenosine receptors to prevent inflammatory skin diseases Exp. Dermatol. 23 2014 553 554
113. M.C. Montesinos, and et al. Promotion of wound healing by an agonist of adenosine A2A receptor is dependent on tissue plasminogen activator Inflammation 38 2015 2036 2041
114. S. Mantell, and et al. Design and application of locally delivered agonists of the adenosine A(2A) receptor Expert. Rev. Clin. Pharmacol. 3 2010 55 72
115. F. Squadrito, and et al. The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial J. Clin. Endocrin. Metab. 99 2014 E746 E753
116. S. Ryzhov, and et al. Role of adenosine A2B receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation Purinergic Signal. 10 2014 477 486
117. S. Ryzhov, and et al. Role of A2B adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells J. Pharmacol. Exp. Ther. 341 2012 764 774
118. S. Ryzhov, and et al. Adenosine A2B receptors on cardiac stem cell antigen (Sca)-1-positive stromal cells play a protective role in myocardial infarction Am. J. Pathol. 183 2013 665 672
119. S. Merighi, and et al. A2a and a2b adenosine receptors affect HIF-1α signaling in activated primary microglial cells Glia 63 2015 1933 1952
120. S. Gessi, and et al. Adenosine modulates HIF-1α, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells Arterioscl. Throm. Vas. 30 2010 90 97
121. S. Gessi, and et al. Adenosine receptors and cancer Biochim. Biophys. Acta 1808 2011 1400 1412
122. S. Gessi, and et al. Downregulation of A(1) and A(2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi Biochim. Biophys. Acta 1822 2012 1660 1670
123. S. Ryzhov, and et al. Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production Mol. Pharmacol. 85 2014 62 73
124. X. Du, and et al. Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells Exp. Biol. Med. 240 2015 1472 1479
125. N. Rudich, and et al. Down-regulation of the A3 adenosine receptor in human mast cells upregulates mediators of angiogenesis and remodeling Mol. Immunol. 65 2015 25 33
126. F.M. Konrad, and et al. Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent FASEB J. 27 2013 3524 3535
127. C.M. Aherne, and et al. Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis Mucosal Immunol. 8 2015 1324 1338
128. U. Schingnitz, and et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury J. Immunol. 184 2010 5271 5279
129. M.L. Hart, and et al. Hypoxia-inducible factor-1(-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor J. Immunol. 186 2011 4367 4374
130. 2B adenosine receptor gene deletion attenuates murine colitis Gastroenterology 135 2008 861 870
131. 2BR expression in non-immune cells plays an important role in the development of murine colitis Dig. Liver Dis. 44 2012 819 826
132. I. Avni, and et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial Ophthalmol. 117 2010 1287 1293
133. P. Fishman, and et al. Targeting the A3 adenosine receptor for glaucoma treatment Mol. Med. Rep. 7 2013 1723 1725
134. S. Bar-Yehuda, and et al. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101 Int. J. Mol. Med. 28 2011 727 731
135. A. Ohta, and M. Sitkovsky Extracellular adenosine-mediated modulation of regulatory T cells Front. Immunol. 5 2014 30
136. M.V. Sitkovsky, and et al. Hostile, hypoxia-A2-Adenosinergic tumor biology as the next barrier to overcome for tumor immunologists Cancer Immunol. Res. 2 2014 598 605
137. L. Antonioli, and et al. Immunity, inflammation and cancer: a leading role for adenosine Nat. Rev. Cancer 13 2013 842 857
138. E. Ntantie, and et al. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering Sci. Signal. 6 2013 ra39
139. S. Gessi, and et al. Adenosine receptor targeting in health and disease Expert Opin. Investig. Drugs 20 2011 1591 1609
140. P. Fishman, and et al. Adenosine receptors and cancer Handb. Exp. Pharmacol. 193 2009 399 441
141. S.M. Stemmer, and et al. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study Oncologist 18 2013 25 32
142. S. Merighi, and et al. Adenosine receptors and diabetes: focus on the A2B adenosine receptor subtype Pharmacol. Res. 99 2015 229 236